TABLE 3.
Patient characteristics
| Success | Failure | p-value+ | |
| Subjects | 27 | 10 | |
| Male/female | 17/10 | 5/5 | 0.71 |
| Age years | 30.9±17.2 | 28.4±9.5 | 0.67 |
| Genotype | 0.50 | ||
| F508del homozygous | 10 (37) | 6 (60) | |
| F508del heterozygous | 15 (55.6) | 4 (40) | |
| Other | 2 (7.4) | 0 | |
| Pancreatic insufficiency | 21 (77.8) | 9 (90) | 0.65 |
| CF-related diabetes | 6 (22.2) | 3 (30) | 0.68 |
| FEV1 % predicted | 66.9±24.1 | 61.5±18.2 | 0.57 |
| Pseudomonas aeruginosa# | 22 (81.5) | 8 (80) | 0.92 |
| Duration of infection weeks¶ | 3.7±6.6 | 2.6±3.1 | 0.60 |
| MRSA carrier nasal/skin swabs | 4 (14.8) | 6 (60) | 0.03 |
Data are presented as n, mean±sd or n (%). CF: cystic fibrosis; FEV1: forced expiratory volume in 1 s; MRSA: methicillin-resistant Staphylococcus aureus. #: chronic colonisation; ¶: interval between first positive culture and start of eradication; +: Chi-squared (Fisher's exact test where appropriate) or t-test.